RecruitingPhase 1NCT07016490

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.

Enrollment

15 participants

Start Date

Jun 12, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Malignant Tumors

Summary

This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SSGJ-709 for people with advanced malignant tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.